Personalized Treatment Plans
496 articles
Targeted Therapy for Cancers Carrying the PALB2 Mutation
Researchers are testing a type of targeted therapy called a PARP inhibitor for cancers carrying the PALB2 mutation.
Cancer Commons: Bringing a Nurse Navigator to Cancer Patients
Nurse navigator Deborah Christensen helps Cancer Commons patients through the maze of clinical trials and treatment options.
Steven Merlin and Davi D’Agostino Team Up to Help Others
Pancreatic cancer patient advocates Steven Merlin and Davi D’Agostino have joined to pool expertise and information for other patients.
Chemotherapy Plus Stem Cell Infusion and Vitamins for BRCA Mutated Pancreatic Cancer
A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.
Comparing the Effectiveness of Vaccine Therapy With or Without Additional Immunotherapy
Can the immunotherapy combination of cancer vaccines and a checkpoint blockade drug work against metastatic pancreatic cancer?
Roberta Luna Gets Real about Pancreatic Cancer
Long-term survivor Roberta Luna has channeled her passion for pancreatic cancer advocacy into a weekly podcast featuring patients, advocacy, medical professionals and more.
Taking a Look At FAK Inhibitors
Dr. Conan Kinsey is looking at how FAK inhibitors can make immunotherapy more effective in combination with chemotherapy.
Finding the Best Diabetes Drug for Pancreatic Cancer Patients
With all the various drugs out there, Dr. James Flory wants to establish which diabetes drug works best for pancreatic cancer patients. Read his expert advice.
Damage as a Way to Repair Pancreatic Cancer
Dr. Talia Golan takes a closer look at the damage caused by the BRCA1/2 mutations to find a way to treat pancreatic cancer.
High-Dose Focused Radiation after Surgical Removal of Pancreatic Tumors
A clinical trial looks at the effectiveness of stereotactic body radiation therapy in killing cancer cells in the margins after pancreatic tumor removal.
Chemo and SBRT for Inoperable Pancreatic Cancer
For inoperable pancreatic cancer, researchers are comparing mFOLFIRINOX and SBRT with gemcitabine-based treatment regimens.
Disappointing Results of a Phase II Trial Using Angiogenesis Inhibitor
Dr. Tanios Bekaii-Saab reports on the disappointing results of a trial combining an angiogenesis inhibitor and mFOLFIRINOX.
ASCO Annual Conference: Highlights in Pancreatic Cancer Research
Dr. Allyson Ocean reviews some of the latest pancreatic cancer research results, including new treatments for some patients.
Comparing Chemotherapy and Radiation Regimens to Prevent Recurrence of Pancreatic Cancer
A clinical trial compares standard chemotherapy with gemcitabine to the combination of chemotherapy with capecitabine and radiation.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.